This new partnership will ensure that NYU Cancer Institute play an active and vital role in WIN’s efforts to translate the most innovative approaches in personalized cancer medicine into patient care worldwide. NYU Cancer Institute is an NCI-designated Comprehensive Cancer Center for more than 33 years, a prestigious ranking conferred to select institutions characterized by scientific excellence, the capability to integrate a diversity of research approaches, and leadership in NCI-funded research efforts.
The WIN Consortium was created to spur collaboration between all stakeholders in personalized cancer medicine and to carry out cross-sector, worldwide clinical trials through the Consortium’s global network of academic and industry partners. With significant ongoing oncologic clinical trials, established multidisciplinary research structures, and a track record of successful research partnerships, NYU Cancer Institute is poised to play an integral role in the Consortium.
“NYU Cancer Institute joining WIN is an important step in the continued development of the Consortium’s capabilities and potential,” stated WIN Consortium Chairman Dr. John Mendelsohn. “The clear strengths NYU brings – experience serving a diverse patient population, excellence in disease-focused and basic science research, and committed, involved leadership – will help speed the translation of personalized cancer medicine innovations into the treatment of cancer patients.”
Dr. William Carroll, Director of the NYU Cancer Institute, noted, “This partnership will provide increased opportunities for the NYU Cancer Institute to play a strong role in innovative, global clinical trials and projects. We believe that this collaboration is strategically significant to advancing the practice of personalized cancer medicine and we look forward to active participation in the Consortium.”
Founded in 2010 on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of 29 leading academic, pharmaceutical, biotech, healthcare IT, and patient advocacy organizations working to accelerate the pace and reduce the cost of translating the most promising advances in genomic-based cancer research into the standard of patient care worldwide. WIN is a non-governmental, not-for-profit organization headquartered in Paris.